XenoTherapeutics Wins ABA’s Best Bioengineering Paper Award for Research on Xeno-Skin™, a Novel Xenotransplantation Treatment for Severe Burns
LAS VEGAS--(BUSINESS WIRE)--Apr 4, 2019--XenoTherapeutics, Inc., a regenerative medicine company specializing in xenotransplantation, received the Burke/Yannas Award for Best Bioengineering Paper today at the 51 st conference of the American Burn Association for its research of Xeno-Skin™. Co-founders Paul Holzer, CEO and Jon Adkins, COO, accepted the award on the company’s behalf.
Xeno-Skin is a first-of-its-kind xenotransplantation product, designed to provide a safe temporary coverage mechanism for patients with severe burn wounds. The winning research demonstrated 30-day efficacy of Xeno-Skin on partial- and full-thickness burn wounds, equal to the duration of allograft comparators in preclinical trials.
XenoTherapeutics is currently enrolling patients for a first-in-human trial of Xeno-Skin at Massachusetts General Hospital.
“Our goal is to advance the field of xenotransplantation to address a critical unmet need for treatment of severe burns. We are humbled by today’s award and excited to execute successful clinical trials in 2019,” said Holzer.
The Burke/Yannas Bioengineering Best Paper Award is granted to original bioengineering research studies in honor of Dr. John F. Burke and Dr. Ioannis V. Yannas, who were instrumental in developing the first artificial skin.
Burn Injuries Worldwide
The World Health Organization reports that globally, burns are responsible for approximately 180,000 deaths annually (2018). The current clinical standard of treatment is human cadaver allograft (HCA). Unfortunately HCA presents infectious disease concerns and the availability is severely limited. Thus, there remains a need for a high quality alternative.
Xeno-Skin is a biologically active, split-thickness, xenotransplantation skin product consisting of dermal and epidermal tissue layers containing vital porcine cells derived from Designated Pathogen Free, “humanized” source animals.
XenoTherapeutics has pioneered the most significant clinical advancement in xenotransplantation in the last 30 years by initiating human trials for the first non-human organ transplant solution, Xeno-Skin TM. Success could help address the critical need for organs and tissues around the globe. XenoTherapeutics supports and adheres to all applicable laws, regulations, and policies governing the ethical treatment of animals, including the Animal Welfare Act and Public Health Service Policy of Humane Care and Use of Laboratory Animals.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190404005735/en/
CONTACT: Mark Steffen
KEYWORD: UNITED STATES NORTH AMERICA NEVADA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY OTHER HEALTH
SOURCE: XenoTherapeutics, Inc.
Copyright Business Wire 2019.
PUB: 04/04/2019 03:03 PM/DISC: 04/04/2019 03:03 PM